NCT04897321 2026-04-15
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Phase 1 Recruiting
Clinical Trials
32 trialsNCT01822652 2026-04-06
GRAIN
Baylor College of Medicine
Phase 1 Active not recruiting
NCT03721068 2026-03-27
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT02298348 2026-03-23
N2013-02
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Active not recruiting
NCT05421897 2026-01-29
RAPID
Children's Hospital Los Angeles
Phase 1 Active not recruiting
NCT01175356 2026-01-23
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Children's Oncology Group
Phase 1 Completed
NCT01953900 2026-01-23
VEGAS
Baylor College of Medicine
Phase 1 Active not recruiting
NCT07358260 2026-01-22
B7-H3.CD28Z.CART in Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT04539366 2025-11-03
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
National Cancer Institute (NCI)
Phase 1 Suspended
NCT03107988 2025-09-15
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT02650648 2025-07-30
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04106219 2025-07-23
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT02030964 2025-02-17
DFMO
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT01798004 2024-07-15
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Children's Oncology Group
Phase 1 Completed
NCT02107963 2024-05-16
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01606878 2024-01-05
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT00885326 2023-04-10
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT02761915 2021-08-17
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
Cancer Research UK
Phase 1 Completed
NCT02390843 2020-04-03
AflacST1402
Emory University
Phase 1 Completed
NCT00007813 2020-02-17
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00877110 2019-01-10
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01576692 2018-11-15
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00960063 2018-08-27
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02439788 2017-06-14
GINAKIT
Baylor College of Medicine
Phase 1 Withdrawn
NCT02457650 2016-08-03
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Shenzhen Second People's Hospital
Phase 1 Unknown
NCT00002740 2014-07-24
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma
Children's Oncology Group
Phase 1 Completed
NCT00003141 2014-03-28
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors
Children's Oncology Group
Phase 1 Completed
NCT00070200 2014-02-13
Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma
Children's Oncology Group
Phase 1 Completed
NCT01048892 2014-01-30
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
Children's Oncology Group
Phase 1 Completed
NCT00075634 2013-09-30
Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00206388 2013-08-02
Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement
Baylor College of Medicine
Phase 1 Completed